The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cladribine Venetoclax in Monocytic AML

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT06232655
Recruitment Status : Not yet recruiting
First Posted : January 31, 2024
Last Update Posted : May 16, 2024
Sponsor:
Collaborator:
The Leukemia and Lymphoma Society
Information provided by (Responsible Party):
University of Colorado, Denver

Brief Summary:
Investigation of Relapsed or refractory AML with a monocytic phenotype after failure of hypomethylating agent+venetoclax

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia Drug: Cladribine Drug: Venetoclax Drug: Azacitidine Phase 2

Detailed Description:
This is an investigator-initiated, open label, single institution, Study to assess the efficacy of Clad/Ven following failure of HMA/Ven in AML with a monocytic phenotype. In cycle 1, subjects will receive cladribine at a dose of 5mg/m2 daily via intravenous infusion on days 1 through 5 and venetoclax 400mg daily (following standard dose escalation over the first 3 days) on days 1 through 28 of a 28 day cycle. A bone marrow biopsy will be performed to assess response on day 28 of cycle 1. Subjects who respond to cycle 1, defined as achieving a CR, CRi, MLFS, or PR per ELN criteria, or a blast reduction of at least 50% from baseline, may continue on alternating 28-day consolidation cycles of Aza/Ven (even cycles) and Clad/Ven (odd cycles). Cycles will continue unless the subject needs to be removed from the study due to disease progression, treatment failure (defined as failure to achieve CR, CRi, or MLFS after 4 cycles of treatment), intolerance or toxicity, patient preference, or other reasons.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Study of Cladribine+Venetoclax After Failure of Venetoclax+Hypomethylating Agent in Monocytic AML
Estimated Study Start Date : December 2024
Estimated Primary Completion Date : October 2026
Estimated Study Completion Date : October 2027


Arm Intervention/treatment
Experimental: Cladribine plus Venetoclax
Subjects will receive cladribine at a dose of 5mg/m2 daily via intravenous infusion on days 1 through 5 of a 28 day cycle. Concomitantly, venetoclax will be administered orally at a dose of 100mg on day 1, 200mg on day 2, and 400mg daily on days 3 through 28.
Drug: Cladribine
A medication used to treat hairy cell leukemia (leukemic reticuloendotheliosis) and B-cell chronic lymphocytic leukemia. Cladribine, sold under the brand name Mavenclad, is used for the treatment of adults with highly active forms of relapsing-remitting multiple sclerosis.
Other Names:
  • Mavenclad
  • Leustatin

Drug: Venetoclax
A medication used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or acute myeloid leukemia (AML).
Other Name: Venclyxto

Experimental: Alternating Aza/Ven and Clad/Ven
Alternating 28-day consolidation cycles of Aza/Ven (even cycles) and Clad/Ven (odd cycles), while those who do not respond will come off the study.
Drug: Cladribine
A medication used to treat hairy cell leukemia (leukemic reticuloendotheliosis) and B-cell chronic lymphocytic leukemia. Cladribine, sold under the brand name Mavenclad, is used for the treatment of adults with highly active forms of relapsing-remitting multiple sclerosis.
Other Names:
  • Mavenclad
  • Leustatin

Drug: Venetoclax
A medication used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or acute myeloid leukemia (AML).
Other Name: Venclyxto

Drug: Azacitidine
Medication used for the treatment of myelodysplastic syndrome, myeloid leukemia, and juvenile myelomonocytic leukemia. It is a chemical analog of cytidine, a nucleoside in DNA and RNA.. Azacitidine and its deoxy derivative, decitabine were first synthesized in Czechoslovakia as potential chemotherapeutic agents for cancer.
Other Names:
  • Vidaza
  • Onureg




Primary Outcome Measures :
  1. Overall response rate (ORR) [ Time Frame: End of Treatment, an average of 6 months ]
    Defined as the proportion of subjects who achieve a CR, CRi, or MLFS that is relapsed after or refractory to HMS/Ven


Secondary Outcome Measures :
  1. Adverse Events [ Time Frame: Duration of Treatment, an average of 6 months ]
    Frequency of adverse events (AEs) and serious adverse events (SAEs)

  2. Event-free survival [ Time Frame: Minimum of 3 years off study ]
    Event-free survival (EFS)

  3. Overall survival [ Time Frame: minimum of 3 years or off study ]
    Overall survival (OS)

  4. Duration of response [ Time Frame: minimum of 3 years or off study ]
    Duration of response (DOR)

  5. Measurable residual disease [ Time Frame: Baseline through End of Treatment, an average of 6 months ]
    Rate of measurable residual disease (MRD)-negativity



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

A subject will be eligible for study participation if they meet the following criteria within 28 days prior to the first day of treatment. Historical records are permitted per investigator discretion.

  1. Subject must have confirmation of non-acute promyelocytic leukemia (APL) Acute Myeloid Leukemia (AML) by the World Health Organization (WHO) criteria with a monocytic or monoblastic phenotype or a Ras pathway mutation.
  2. The subject's AML must be relapsed after or refractory to prior treatment with hypomethylating agent (HMA) and venetoclax combination.

    Note: other prior line(s) of therapy including stem cell transplant (SCT) are allowed, but HMA/Ven must be one of the preceding treatments. Subjects who have progressed to AML after prior treatment with HMA/Ven for high grade Chronic Myelomonocytic Leukemia (CMML) or Myelodysplastic Syndrome (MDS) are also eligible.

  3. Age ≥ 18 years
  4. Projected life expectancy of at least 12 weeks
  5. Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2
  6. Adequate renal function as demonstrated by a calculated creatinine clearance ≥ 60 mL/min, calculated using the formula CKD-EPI Creatinine Equation (2021).
  7. Adequate liver function, as demonstrated by:

    • Aspartate aminotransferase (AST) ≤ 3.0 x ULN*
    • Alanine aminotransferase (ALT) ≤ 3.0 x ULN*
    • Total bilirubin ≤ 1.5 x ULN, unless considered to be due to leukemic organ involvement or Gilbert's syndrome* *In subjects with Gilbert's syndrome, bilirubin needs to be ≤ 4 x ULN
  8. Non-sterile male subjects must use contraceptive methods with partner(s) at least prior to beginning study drug administration and continuing up to 90 days after the last dose of study drug. Male subjects must agree to refrain from sperm donation from initial study drug administration until 90 days after the last dose of study drug. No contraception is required if male subjects are surgically sterile (vasectomy with medical assessment confirming surgical success) or if the male subject has a female partner who is postmenopausal or permanently sterile (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).
  9. Female subjects must be either:

    • Postmenopausal: defined as age > 60 years with no menses for 12 or more months without an alternative medical cause; OR
    • Permanently surgically sterile (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy); OR
    • If subject is of childbearing potential, use of contraception is required while on study treatment and for 6 months after the last dose.
  10. Subject must voluntarily sign an informed consent, approved by the Institutional Research Board (IRB), prior to the initiation of any research-related screening or study procedures.

Exclusion Criteria:

  1. Subject has received prior treatment with cladribine for AML.
  2. Subject has a white blood cell count > 25 x 109/L. Note: hydroxyurea and/or leukapheresis are permitted to meet this criterion.
  3. Subject has known active central nervous system (CNS) involvement of AML.
  4. Subject exhibits evidence of uncontrolled systemic infection requiring therapy (viral, bacterial, or fungal). Uncontrolled is defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment. Patients on antibiotics, antivirals, or antifungals with controlled systemic symptoms will not be excluded.
  5. Subject has any clinically significant condition(s) that in the opinion of the investigator would adversely affect his/her participating in this study, including but not limited to:

    • New York Heart Association heart failure > class 2
    • Renal, neurologic, psychiatric, endocrine, metabolic, immunologic, hepatic, cardiovascular disease, or bleeding disorder independent of leukemia.
  6. Subject has a QTc interval > 470 msec.
  7. Subject has a history of other malignancies within 2 years prior to study entry, with the following exceptions:

    • Adequately treated in situ carcinoma of the breast or cervix
    • Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin
    • Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent
    • Prostate cancer not requiring therapy beyond hormonal therapy
  8. Subject is pregnant or breastfeeding.
  9. Subject is known to be positive for HIV. HIV testing is not required.
  10. Subject is known to be positive for hepatitis B or C infection with the exception of those with an undetectable viral load. Hepatitis B or C testing is not required, and subjects with serologic evidence of prior vaccination to HBV may participate.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06232655


Contacts
Layout table for location contacts
Contact: Derek Schatz 720-848-0628 derek.schatz@cuanschutz.edu

Locations
Layout table for location information
United States, Colorado
Colorado Research Center
Aurora, Colorado, United States, 80045
Contact: Derek Schatz    720-848-0628    derek.schatz@cuanschutz.edu   
Principal Investigator: Christine McMahon, MD         
Sponsors and Collaborators
University of Colorado, Denver
The Leukemia and Lymphoma Society
Investigators
Layout table for investigator information
Principal Investigator: Christine McMahon, MD University of Colorado, Denver
Layout table for additonal information
Responsible Party: University of Colorado, Denver
ClinicalTrials.gov Identifier: NCT06232655    
Other Study ID Numbers: 23-0273.cc
First Posted: January 31, 2024    Key Record Dates
Last Update Posted: May 16, 2024
Last Verified: May 2024

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by University of Colorado, Denver:
Relapsed
Refractory
Additional relevant MeSH terms:
Layout table for MeSH terms
Azacitidine
Venetoclax
Cladribine
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs